Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 14/20 | 0.75 |
| ▸ | FYN | P06241 | 3/20 | 0.75 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516852 | 0.91 | CHEK2 (0.88) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL4620246 | 0.86 | CHEK2 (1.00) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL18613241 | 0.86 | FYN (1.00) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL13977050 | 0.84 | CHEK2 (0.77) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL2224862 | 0.84 | CHEK2 (0.72) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL17011909 | 0.82 | CHEK2 (0.73) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL12077792 | 0.82 | CHEK2 (0.87) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL12078010 | 0.81 | MAP4K4 (0.79) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL12078349 | 0.81 | CHEK2 (0.72) | CHEK2FYNMKNK1MAP4K4CHEK1 | |
| SCHEMBL2225807 | 0.80 | MAP4K4 (1.00) | CHEK2FYNMKNK1MAP4K4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | CHEK2 4817/4885FYN 3839/4885MKNK1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.